CD8A and neoplasm: Furthermore, analysis of the tumor‐infiltrating lymphocyte (TILs) profile revealed that TZ‐dSA3‐12 increased the proportion of tumor‐infiltrating CD8+ T cells compared to monotherapy (Figure 8f).